Collagen-based dermal fillers: past, present, future

Area of Science:

• Dermatology
• Cosmetic Surgery
• Biomaterials

Background:

• Collagen was the first FDA-approved dermal filler for cosmetic facial treatments.
• Bovine collagen products like Zyderm and Zyplast were introduced in the early 1980s.
• The market for dermal fillers has significantly evolved over the past two decades.

Purpose of the Study:

• To review the historical benefits and risks associated with collagen injections.
• To discuss typical outcomes and patient experiences with collagen fillers.
• To analyze the reasons for collagen's declining market share in facial aesthetics.

Main Methods:

• Historical review of collagen filler approvals and usage.
• Analysis of reported side effects, particularly allergic reactions.
• Comparison of collagen filler efficacy and longevity with newer alternatives.
• Examination of histopathologic data on collagen persistence.

Main Results:

• Collagen injections require mandatory skin testing, causing inconvenience and potential delays.
• A negative skin test does not eliminate the risk of allergic reactions or adverse events.
• Perceived clinical efficacy of collagen fillers is often short-lived, with persistence limited to approximately 9 months.
• Hyaluronic acid and other newer fillers have led to a significant loss of market share for collagen.

Conclusions:

• The risks, including allergies, and limited duration of benefit have diminished the role of collagen fillers.
• The inconvenience of mandatory skin testing further contributes to the decline of collagen use.
• Advancements in dermal filler technology have provided safer and more effective alternatives to collagen.